AstraZeneca has reduced about 600 positions in its respiratory and immunology sales teams in the US as part of a wider plan to improve efficiency and redirect resources toward future growth areas.
The workforce changes are linked to the company’s long-term restructuring programme, which aims to generate significant cost savings by 2029. However, the move is not being positioned as a company-wide shrinkage exercise. Instead, AstraZeneca says the focus is on moving talent and investments toward products, research programmes and business areas with stronger growth potential.
Not all affected employees are expected to leave the organisation. Some may be redeployed into other roles as the company reshapes its workforce to match changing business needs.
The cuts come as some respiratory products have struggled to deliver strong sales growth in the US market. At the same time, other medicines in AstraZeneca’s portfolio are gaining momentum and creating new opportunities for investment and expansion.
For HR leaders, the development highlights a growing trend across industries: workforce reallocation rather than simple headcount reduction. Companies are increasingly moving employees, skills and budgets from slower-growing business segments to areas expected to drive future revenue.
AstraZeneca has indicated that more workforce adjustments may occur as part of the multi-year transformation programme. Alongside role reductions in some functions, the company expects to create opportunities for reskilling, upskilling and internal mobility in emerging areas of the business.
The case underscores how organisations are balancing cost pressures with growth ambitions. While some employees face uncertainty during restructuring, companies are increasingly focusing on skill redevelopment and talent redeployment to ensure they have the workforce needed for future business priorities.


